Table 4.

Exposure-adjusted event rates for grade ≥3 treatment-emergent AEs of clinical interest

Blinatumomab, N = 267 (total treatment exposure, 89.0 y)SOC chemotherapy, N = 109 (total treatment exposure, 14.8 y)
No. of eventsExposure-adjusted event rate*No. of eventsExposure-adjusted event rate*P
Cytokine release syndrome 14 0.16 .038 
 Cytokine release syndrome 0.10 .096 
 Hematophagic histiocytosis 0.06 — 
 Cytokine storm — 
Tumor lysis syndrome 0.09 0.07 .780 
Acute pancreatitis 0.01 0.07 .232 
Neurologic events 34 0.38 14 0.95 .008§ 
 Headache 0.01 0.20 .006§ 
 Insomnia 0.01 — 
 Tremor 0.01 — 
 Dizziness 0.01 — 
 Somnolence 0.03 — 
 Seizure 0.02 0.20 .018§ 
Gastrointestinal disorders 25 0.28 22 1.49 <.001§ 
 Diarrhea 0.03 0.07 .572 
 Nausea 0.20 — 
 Constipation — 
 Vomiting 0.07 — 
 Stomatitis 0.05 0.14 .240 
 Abdominal pain 0.05 0.34 .004§ 
 Dyspepsia — 
Infections 145 1.63 96 6.49 <.001§ 
Cytopenias 324 3.64 297 20.07 <.001§ 
 Febrile neutropenia 71 0.80 48 3.24 <.001§ 
 Neutropenia 77 0.87 41 2.77 <.001§ 
 Thrombocytopenia 71 0.80 97 6.55 <.001§ 
 Decreased platelets 33 0.37 64 4.32 <.001§ 
 Decreased white blood cells 20 0.23 0.54 .051 
 Decreased neutrophils 17 0.19 22 1.49 <.001§ 
 Leukopenia 18 0.20 0.34 .335 
 Decreased lymphocytes 0.03 0.27 .008§ 
 Lymphopenia 0.01 — 
Elevated liver enzymes 58 0.65 28 1.89 <.001§ 
Progressive multifocal leukoencephalopathy 0.03 — 
Decreased immunoglobulins 0.08 — 
Other AEs of interest     
 Pyrexia 22 0.25 0.54 .076 
 Anemia 100 1.12 81 5.47 <.001§ 
Blinatumomab, N = 267 (total treatment exposure, 89.0 y)SOC chemotherapy, N = 109 (total treatment exposure, 14.8 y)
No. of eventsExposure-adjusted event rate*No. of eventsExposure-adjusted event rate*P
Cytokine release syndrome 14 0.16 .038 
 Cytokine release syndrome 0.10 .096 
 Hematophagic histiocytosis 0.06 — 
 Cytokine storm — 
Tumor lysis syndrome 0.09 0.07 .780 
Acute pancreatitis 0.01 0.07 .232 
Neurologic events 34 0.38 14 0.95 .008§ 
 Headache 0.01 0.20 .006§ 
 Insomnia 0.01 — 
 Tremor 0.01 — 
 Dizziness 0.01 — 
 Somnolence 0.03 — 
 Seizure 0.02 0.20 .018§ 
Gastrointestinal disorders 25 0.28 22 1.49 <.001§ 
 Diarrhea 0.03 0.07 .572 
 Nausea 0.20 — 
 Constipation — 
 Vomiting 0.07 — 
 Stomatitis 0.05 0.14 .240 
 Abdominal pain 0.05 0.34 .004§ 
 Dyspepsia — 
Infections 145 1.63 96 6.49 <.001§ 
Cytopenias 324 3.64 297 20.07 <.001§ 
 Febrile neutropenia 71 0.80 48 3.24 <.001§ 
 Neutropenia 77 0.87 41 2.77 <.001§ 
 Thrombocytopenia 71 0.80 97 6.55 <.001§ 
 Decreased platelets 33 0.37 64 4.32 <.001§ 
 Decreased white blood cells 20 0.23 0.54 .051 
 Decreased neutrophils 17 0.19 22 1.49 <.001§ 
 Leukopenia 18 0.20 0.34 .335 
 Decreased lymphocytes 0.03 0.27 .008§ 
 Lymphopenia 0.01 — 
Elevated liver enzymes 58 0.65 28 1.89 <.001§ 
Progressive multifocal leukoencephalopathy 0.03 — 
Decreased immunoglobulins 0.08 — 
Other AEs of interest     
 Pyrexia 22 0.25 0.54 .076 
 Anemia 100 1.12 81 5.47 <.001§ 

—, not estimable.

*

Per patient-year.

P value comparing blinatumomab vs SOC from a Poisson regression model using number of AEs as the dependent variable and log(exposure time) as offset.

Favors SOC.

§

Favors blinatumomab arm.

or Create an Account

Close Modal
Close Modal